🇺🇸 FDA
Pipeline program

Placebo to match LY3537982, PEMBROLIZUMAB , PEMETREXED , CARBOPLATIN , CISPLATIN

J3M-MC-JZQB

Phase 3 small_molecule active

Quick answer

Placebo to match LY3537982, PEMBROLIZUMAB , PEMETREXED , CARBOPLATIN , CISPLATIN for Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cancer is a Phase 3 program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).

Program details

Company
Eli Lilly Co.
Indication
Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials